这是indexloc提供的服务，不要输入任何密码
Skip to main content

Advertisement

Springer Nature Link
Log in

Evolution of ophthalmological care in adult with diabetes in France between 2010 and 2022: a nationwide study

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

A Correction to this article was published on 19 May 2025

This article has been updated

Abstract

Purpose

The aim of this study is to describe ophthalmological care of adults with diabetes in France and its evolution between 2010 and 2022.

Methods

In this study, we used the ESND, a representative permanent random sample of 2/100th of the entire French population. Ophthalmological care was defined by the combination of ophthalmological procedures (fundus examination, color fundus photography, Optical Coherence Tomography..) and/or ophthalmological treatment (intravitreal injection or laser treatment) during the year. Changes in annual rates during the study period were assessed using linear regression models excluding 2020.

Results

From 2010 to 2022, the number of adults treated for diabetes in the ENSD increased from 48 329 patients (mean age 65.3 ± 13.0, 46.3% women) to 68 397 patients (mean age 67.0 ± 13.2, 44.8% women). Among them, the annual rate of ophthalmological care was stable (46.5% in 2010 and 48.5% in 2022) and the difference was not significant (β = 0.10% per year, p = 0.11). The yearly ophthalmological treatment rate increased significantly (3.3% in 2010 and 5.3% in 2022, β = 0.2% per year, p < 0.0001). Rates were lower during the COVID-19 outbreak in 2020.Women, individuals aged between 66–80 years, those living in the least deprived areas and those treated with combined insulin and non-insulin treatment had higher yearly ophthalmological care rate.

Conclusion

In this large nationwide representative study with recent and updated data, although ophthalmological treatment rate has increased over the decade mainly due to intravitreal injections, less than half of the diabetic patients receive yearly ophthalmological care.

AbstractSection Key messages AbstractSection What is known

  • Ophthalmological care for diabetic patients has been reported to be sub-optimal, but recent trends are less known.

  • In this study, conducted in a nationwide representation sample of diabetic patients with recent and updated data, less than half of the diabetic patients receive yearly ophthalmological care.

AbstractSection What is new

  • The ophthalmological treatment rate has increased over the decade mainly due to intravitreal injections.

  • The highest rates of ophthalmological care are observed among diabetic women, patients aged 66 to 80, and those receiving combined antidiabetic therapy. All the rates are impacted by the COVID-19 outbreak.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

Change history

References

  1. Simó-Servat O, Hernández C, Simó R (2019) Diabetic Retinopathy in the Context of Patients with Diabetes. Ophthalmic Res 62(4):211–217. https://doi.org/10.1159/000499541

    Article  PubMed  CAS  Google Scholar 

  2. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T (2012) Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care 35:556–564

    Article  PubMed  PubMed Central  Google Scholar 

  3. Teo ZL, Tham Y-C, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, Tang Y, Lu Y, Wong IY, Ting DSW, Tan GSW, Jonas JB, Sabanayagam C, Wong TY, Cheng C-Y (2021) Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology 128(11):1580–1591. https://doi.org/10.1016/j.ophtha.2021.04.027

    Article  PubMed  Google Scholar 

  4. Wong TY, Cheung CMG, Larsen M, Sharma S, Simó R (2016) Diabetic retinopathy. Nat Rev Dis Prim 2(1):1–17. https://doi.org/10.1038/nrdp.2016.12

    Article  Google Scholar 

  5. Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ (2021) Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabet Investig 12(8):1322–1325. https://doi.org/10.1111/jdi.13480

    Article  Google Scholar 

  6. Vujosevic S, Aldington SJ, Silva P, Hernández C, Scanlon P, Peto T, Simó R (2020) Screening for diabetic retinopathy : New perspectives and challenges. Lancet Diabet Endocrinol 8(4):337–347. https://doi.org/10.1016/S2213-8587(19)30411-5

    Article  Google Scholar 

  7. Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, Maia M, Mathenge W, Moreker S, Muqit MMK, Resnikoff S, Verdaguer J, Zhao P, Ferris F, Aiello LP, Taylor HR (2018) Guidelines on Diabetic Eye Care. Ophthalmology 125(10):1608–1622. https://doi.org/10.1016/j.ophtha.2018.04.007

    Article  PubMed  Google Scholar 

  8. Scanlon PH (2017) The English National Screening Programme for diabetic retinopathy 2003–2016. Acta Diabetol 54(6):515–525. https://doi.org/10.1007/s00592-017-0974-1

    Article  PubMed  PubMed Central  Google Scholar 

  9. Liew G, Michaelides M, Bunce C (2014) A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open 4(2):e004015. https://doi.org/10.1136/bmjopen-2013-004015

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wang LZ, Cheung CY, Tapp RJ, Hamzah H, Tan G, Ting D, Lamoureux E, Wong TY (2017) Availability and variability in guidelines on diabetic retinopathy screening in Asian countries. Br J Ophthalmol 101(10):1352–1360. https://doi.org/10.1136/bjophthalmol-2016-310002

    Article  PubMed  Google Scholar 

  11. An J, Niu F, Turpcu A, Rajput Y, Cheetham TC (2018) Adherence to the American Diabetes Association retinal screening guidelines for population with diabetes in the United States. Ophthalmic Epidemiol 25(3):257–265. https://doi.org/10.1080/09286586.2018.1424344

    Article  PubMed  Google Scholar 

  12. Cougnard-Grégoire A, Korobelnik JF, Delyfer MN, Rigalleau V, Daien V, Creuzot-Garcher C, Delcourt C (2020) Trends in the use of eye care services in adults treated for diabetes between 2008 and 2017 in France: a nationwide study. Ophthalmic Res 63(5):452–459

    Article  PubMed  Google Scholar 

  13. Delcourt C, Massin P, Rosilio M (2009) Epidemiology of diabetic retinopathy- Contrast between the expected prevalence and the frequency of reported cases in the French population. Diabetes Metab 35:431–438

    Article  PubMed  CAS  Google Scholar 

  14. De Germay, S., Conte, C., Micallef, J., Bouquet, E., Chouchana, L., Lafaurie, M., Pariente, A., & Pharmacoepidemiological group of the French Society of Pharmacology and Therapeutics (SFPT) (2023) Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice. Therapie 78(6):679–689. https://doi.org/10.1016/j.therap.2023.01.009

    Article  Google Scholar 

  15. Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, Moore N (2017) The national healthcare system claims databases in France, SNIIRAM and EGB : Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 26(8):954–962. https://doi.org/10.1002/pds.4233

    Article  PubMed  Google Scholar 

  16. Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, Zureik M (2021) Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France : A cohort study of 66 million people. Lancet Regional Health - Eur 8:100158. https://doi.org/10.1016/j.lanepe.2021.100158

    Article  Google Scholar 

  17. Health Data Hub (2023) Publication de la procédure d’accès simplifié à l’ESND, nouvel échantillon du SNDS remplaçant l’EGB. Health Data Hub. https://www.health-data-hub.fr/actualites/publication-de-la-procedure-dacces-simplifie-lesnd-nouvel-echantillon-du-snds-remplacant. Accessed 1 Sep 2024

  18. Fuentes, S., Cosson, E., Mandereau-Bruno, L., Fagot-Campagna, A., Bernillon, P., Goldberg, M., Fosse-Edorh, S., & CONSTANCES-Diab Group (2019) Identifying diabetes cases in health administrative databases : A validation study based on a large French cohort. Int J Public Health 64(3):441–450. https://doi.org/10.1007/s00038-018-1186-3

    Article  Google Scholar 

  19. Bour T (2014) La cotation des actes avec la CCAM Rappel de quelques règles de bonne conduite. Les Cahiers d’Ophtalmologie 179(70–6):58

    Google Scholar 

  20. Rey G, Jougla E, Fouillet A, Hémon D (2009) Ecological association between a deprivation index and mortality in France over the period 1997–2001: Variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Publc Health 9:33. https://doi.org/10.1186/1471-2458-9-33

    Article  Google Scholar 

  21. Drusch S, Le Tri T, Ankri J, Zureik M, Herr M (2021) Decreasing trends in potentially inappropriate medications in older people: a nationwide repeated cross-sectional study. BMC Geriatr 21:1–11

    Article  Google Scholar 

  22. Haute Autorité de Santé (2010) Dépistage de la rétinopathie diabétique par lecture différée de photographies du fond d’œil. https://www.has-sante.fr/upload/docs/application/pdf/2011-03/synthese_et_recos_depistage_de_la_rd_vf_2011-03-02_15-09-1_169.pdf. Accessed 22 Apr 2024

  23. Chamard C, Daien V, Erginay A, Gautier J-F, Villain M, Tadayoni R, Carriere I, Massin P (2021) Ten-year incidence and assessment of safe screening intervals for diabetic retinopathy: The OPHDIAT study. Br J Ophthalmol 105(3):432–439. https://doi.org/10.1136/bjophthalmol-2020-316030

    Article  PubMed  Google Scholar 

  24. Grauslund J (2022) Diabetic retinopathy screening in the emerging era of artificial intelligence. Diabetologia 65(9):1415–1423. https://doi.org/10.1007/s00125-022-05727-0

    Article  PubMed  Google Scholar 

  25. Bellemo V, Lim G, Rim TH, Tan GSW, Cheung CY, Sadda S, He M, Tufail A, Lee ML, Hsu W, Ting DSW (2019) Artificial Intelligence Screening for Diabetic Retinopathy: The Real-World Emerging Application. Curr DiabRep 19(9):72. https://doi.org/10.1007/s11892-019-1189-3

    Article  Google Scholar 

  26. Grzybowski A, Brona P, Lim G, Ruamviboonsuk P, Tan GSW, Abramoff M, Ting DSW (2020) Artificial intelligence for diabetic retinopathy screening: A review. Eye 34(3):451–460. https://doi.org/10.1038/s41433-019-0566-0

    Article  PubMed  Google Scholar 

  27. Van der Heijden AA, Abramoff MD, Verbraak F, van Hecke MV, Liem A, Nijpels G (2018) Validation of automated screening for referable diabetic retinopathy with the IDx-DR device in the Hoorn Diabetes Care System. Acta Ophthalmol 96(1):63–68. https://doi.org/10.1111/aos.13613

    Article  PubMed  Google Scholar 

  28. Wewetzer L, Held LA, Goetz K, Steinhäuser J (2023) Determinants of the implementation of artificial intelligence-based screening for diabetic retinopathy—A cross-sectional study with general practitioners in Germany. Digital Health 9:20552076231176644. https://doi.org/10.1177/20552076231176644

    Article  PubMed  PubMed Central  Google Scholar 

  29. Jani PD, Forbes L, Choudhury A, Preisser JS, Viera AJ, Garg S (2017) Evaluation of Diabetic Retinal Screening and Factors for Ophthalmology Referral in a Telemedicine Network. JAMA Ophthalmol 135(7):706–714. https://doi.org/10.1001/jamaophthalmol.2017.1150

    Article  PubMed  PubMed Central  Google Scholar 

  30. Sachdeva A, Stratton IM, Unwin J, Moreton R, Scanlon PH (2012) Diabetic retinopathy screening: study to determine risk factors for non-attendance. Diabet Primary Care 14(5):308–316

    Google Scholar 

  31. Lake AJ, Browne JL, Rees G, Speight J (2017) What factors influence uptake of retinal screening among young adults with type 2 diabetes? A qualitative study informed by the theoretical domains framework. J Diabet Complications 31(6):997–1006. https://doi.org/10.1016/j.jdiacomp.2017.02.020

    Article  Google Scholar 

  32. Creuzot-Garcher C, Massin P, Srour M, Baudin F, Dot C, Nghiem-Buffet S, Girmens J-F, Collin C, Ponthieux A, Delcourt C (2022) Epidemiology of Treated Diabetes Ocular Complications in France 2008–2018—The LANDSCAPE French Nationwide Study. Pharmaceutics 14(11):11. https://doi.org/10.3390/pharmaceutics14112330

    Article  Google Scholar 

  33. Yin L, Zhang D, Ren Q, Su X, Sun Z (2020) Prevalence and risk factors of diabetic retinopathy in diabetic patients. Medicine 99(9):e19236. https://doi.org/10.1097/MD.0000000000019236

    Article  PubMed  PubMed Central  Google Scholar 

  34. Baumeister SE, Schomerus G, Andersen RM, Tost F, Markus MRP, Völzke H, Jürgens C (2015) Trends of barriers to eye care among adults with diagnosed diabetes in Germany, 1997–2012. Nutr Metab Cardiovasc Dis 25(10):906–915. https://doi.org/10.1016/j.numecd.2015.07.003

    Article  PubMed  CAS  Google Scholar 

  35. Thykjær AS, Andersen N, Bek T, Heegaard S, Hajari J, Laugesen CS, Möller S, Pedersen FN, Rosengaard L, Schielke KC, Kawasaki R, Højlund K, Rubin KH, Stokholm L, Grauslund J (2022) Attendance in a national screening program for diabetic retinopathy: A population-based study of 205,970 patients. Acta Diabetol 59(11):1493–1503. https://doi.org/10.1007/s00592-022-01946-4

    Article  PubMed  PubMed Central  Google Scholar 

  36. Nissen TPH, Vestergaard P, Vorum H, Torp-Pedersen C, Aasbjerg K (2023) A cohort follow-up study for diabetic retinopathy screening incidence in the North Denmark Region. Acta Diabetol 60(11):1581–1590. https://doi.org/10.1007/s00592-023-02146-4

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Cheyne, C. P., Burgess, P. I., Broadbent, D. M., García-Fiñana, M., Stratton, I. M., Criddle, T., Wang, A., Alshukri, A., Rahni, M. M., Vazquez-Arango, P., Vora, J. P., Harding, S. P., & Group, I. S (2021) Incidence of sight-threatening diabetic retinopathy in an established urban screening programme : An 11-year cohort study. Diabet Med 38(9):e14583. https://doi.org/10.1111/dme.14583

    Article  Google Scholar 

  38. WHO (2021) Diabetic retinopathy screening: a short guide. Increase effectiveness, maximize benefits and minimize harm. https://iris.who.int/bitstream/handle/10665/336660/9789289055321-eng.pdf?sequence=1. Accessed 22 Apr 2024

  39. The Diabetic Retinopathy Clinical Research Network (2015) Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med 372(13):1193–1203. https://doi.org/10.1056/NEJMoa1414264

    Article  PubMed Central  CAS  Google Scholar 

  40. Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, Shah C, Rosberger D, Sun JK (2019) Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab. JAMA Ophthalmology 137(9):977–985. https://doi.org/10.1001/jamaophthalmol.2019.1963

    Article  PubMed  PubMed Central  Google Scholar 

  41. Open Medic (2024) Open medic : base complète sur les dépenses de médicaments interrégimes - data.gouv.fr. https://www.data.gouv.fr/fr/datasets/open-medic-base-complete-sur-les-depenses-de-medicaments-interregimes/. Accessed 10 June 2024

  42. Al Dhibi HA, Arevalo JF (2013) Clinical trials on corticosteroids for diabetic macular edema. World J Diabetes 4(6):295–302. https://doi.org/10.4239/wjd.v4.i6.295

    Article  PubMed  PubMed Central  Google Scholar 

  43. Boscia F, Veritti D, Iaculli C, Lattanzio R, Freda S, Piergentili B, & Varano M. (2024). Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data. European Journal of Ophthalmology, 11206721241237069. https://doi.org/10.1177/11206721241237069

  44. Creuzot Garcher CP, Massin P, Srour M, Baudin F, Dot C, Nghiem-Buffet S, Girmens J-F, Collin C, Ponthieux A, Delcourt C (2024) Management of diabetic macular oedema in France from 2012 to 2018: The nationwide LANDSCAPE study. Acta Ophthalmol 102(4):e548–e556. https://doi.org/10.1111/aos.15799

    Article  PubMed  Google Scholar 

  45. Weill A, Drouin J, Desplas D, Cuenot F, Dray-Spira R, Zureik M (2020) Usage des médicaments de ville en France durant l’épidémie de la Covid-19 – point de situation après les 8 semaines de confinement et une semaine de post-confinement (jusqu’au 17 mai 2020) EPIPHARE Groupement d’intérêt scientifique (GIS) ANSM-CNAM. https://www.epi-phare.fr/rapports-detudes-et-publications/covid-19-usage-des-medicaments-de-ville-en-france-3/. Accessed 20 Jan 2025

  46. Weill A, Drouin J, Desplas D, Cuenot F, Dray-Spira R, Zureik M (2021) Usage des médicaments de ville en France durant l’épidémie de la Covid-19 – point de situation après les 8 semaines de confinement et une semaine de post-confinement (jusqu’au 25 avril 2021) (2021). EPIPHARE Groupement d’intérêt scientifique (GIS) ANSM-CNAM. https://www.epi-phare.fr/rapports-detudes-et-publications/covid-19-usage-des-medicaments-rapport-6/. Accessed 20 Jan 2025

  47. Billioti de Gage S, Drouin J, Desplas D, Cuenot F, Dray-Spira R, Weill A, Zureik M (2021) Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic. JAMA Ophthalmol 139(2):240–242. https://doi.org/10.1001/jamaophthalmol.2020.5594

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Ophthalmology Department, AP-HP, Hôpital Lariboisière, Université Paris Cité, 2 Rue Ambroise Paré, 75010, Paris, France

    Abir Zureik & Aude Couturier

  2. University Bordeaux, INSERM, BPH, U1219, F-33000, Bordeaux, France

    Abir Zureik & Cécile Delcourt

  3. Retina Department, Foundation Adolphe de Rothschild Hospital, 25-29 Rue Manin, 75019, Paris, France

    Aude Couturier

Authors
  1. Abir Zureik
    View author publications

    Search author on:PubMed Google Scholar

  2. Aude Couturier
    View author publications

    Search author on:PubMed Google Scholar

  3. Cécile Delcourt
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Abir Zureik.

Ethics declarations

Ethical approval

There was no requirement for ethical approval or data protection agency approval because of the anonymized nature of the database. This study was thus exempt from a review by an ethical committee, and written consent was not required, according to French legislation. This study conformed to the provisions of the Declaration of Helsinki in 1995 (and revised in Edinburgh 2000).

Conflicts of interest

The following authors have no conflict of interest to disclose: Abir Zureik.

Cécile Delcourt is consultant for Allergan, Théa Pharma and Novartis.

Aude Couturier is consultant for AbbVie, Bayer, Horus, Novartis, Roche and Zeiss.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised. The first bullet in the key messages is now corrected.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 190 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zureik, A., Couturier, A. & Delcourt, C. Evolution of ophthalmological care in adult with diabetes in France between 2010 and 2022: a nationwide study. Graefes Arch Clin Exp Ophthalmol 263, 1553–1564 (2025). https://doi.org/10.1007/s00417-025-06793-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-025-06793-x

Keywords